Intec Pharma Announces $10 Million Private Placement

Intec Pharma Ltd. , a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, today announced that it has entered into agreements with several investors for the private placement of 2,289,638 ordinary shares of the Company, at a price of The ordinary shares to be issued by Intec in the private placement have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in , absent registration under the Securities Act and applicable state securities laws or an applicable exemption from those registration requirements.

Precise technique tracks dopamine in the brain

User warning : Table doesn't exist query: SELECT * FROM prpcom_node_field_instance nfi LEFT JOIN prpcom_node_field nf ON nf.field_name = nfi.field_name WHERE nf.active = 1 AND nfi.widget_active = 1 in _db_query() . Warning : Invalid argument supplied for foreach() in content_views_data() .

Fundraiser Finlay, ten, says: ‘I wanted to help ALL grandads!’

WHEN ten-year-old Finlay Rowan decided to help other people like his grandad who are suffering from Parkinson’s Disease, he enlisted the help of his mum. “He told me he wanted to have his head shaved to raise funds for Parkinson’s UK – and he said, ”Will you do it with me?’ I couldn’t really say no, could I?” laughed Wendy, of Eldwick , Bingley .

Costly Parkinson’s treatment to be covered for ‘small group’ of British Columbians

A small number of British Columbians suffering from Parkinson’s disease will soon be able to try the costly medication Duodopa, with fees covered by the province, as long as they have no other option of treatment. In a statement released Tuesday, Health Minister Terry Lake said he’s been in discussion with Parkinson Society British Columbia and the Pacific Parkinson’s Research Centre about the high cost of the drug and its effectiveness.

Parkinson’s patients fight disease with boxing

Jim Duelley fires off two left punches, a right punch, then a left hook into boxing trainer Byron Higinbotham’s punch mitts. After practicing the four-part combination, the former firefighter moves to other stations at Higs Gym in Central Point, pounding a heavy bag, working the speed bag and perfecting other two- to seven-punch combinations.

Simple blood test may be accurate in differentiating between Parkinson’s disease and APDs

A simple blood test may be as accurate as a spinal fluid test when trying to determine whether symptoms are caused by Parkinson’s disease or another atypical parkinsonism disorder, according to a new study published in the February 8, 2017, online issue of Neurology, the medical journal of the American Academy of Neurology. In early stages of disease, it can be difficult to differentiate between Parkinson’s disease and atypical parkinsonism disorders like multiple system atrophy, progressive supranuclear palsy and corticobasal degeneration, because symptoms can overlap.

Monitoring of 30 marker candidates in early Parkinson disease as progression markers.

This was a longitudinal single-center cohort study to comprehensively explore multimodal progression markers for Parkinson disease in patients with recently diagnosed PD and age-matched, neurologically healthy controls . Thirty tests at baseline and after 24 months covered nonmotor symptoms , cognitive function, and REM sleep behavior disorder by polysomnography , voxel-based morphometry of the brain by MRI, and CSF markers.

Addex’s Clinical Programs and Discovery Platform Highlighted in…

Addex Therapeutics announced today the publication of a review summarizing the current status of allosteric modulators as potential novel treatments for neurodegenerative diseases, such as Parkinson’s and Alzheimer’s disease, in Current Opinion in Pharmacology . This review highlights the important contribution Addex has made in the discovery of allosteric modulator compounds.

Experts find two mechanisms involved in making decisions

Scientists have identified two distinct mechanisms in the human brain that control the balance between speed and accuracy when making decisions. One network increases the amount of information needed to make accurate choices, while the other tends to lower this threshold for quick decision making.

Neuroinflammation Induces Neurodegeneration.

Neurodegenerative diseases such as Alzheimer’s disease , Parkinson’s disease , and Multiple Sclerosis are characterized by neuronal degeneration and neuronal death in specific regions of the central nervous system . In AD, neurons of the hippocampus and entorhinal cortex are the first to degenerate, whereas in PD, dopaminergic neurons in the substantia nigra degenerate.

Artist exhibits prints of sliced human brains at Cambridge’s…

Passing Thoughts 13, created by Artist Susan Aldworth printed directly from slices of human brains which forms part of the Realisation exhibition aiming to raise awareness of the need for brain donation and research into Parkinson’s disease. Artwork printed directly from slices of human brains forms part of a Cambridge exhibition aiming to raise awareness of the need for brain donation and research into Parkinson’s disease.

Year begins for Parkinsong

On Song: Robyn Sharpe, Jeanette Pritchett, Lyn Lehane, Len Hoy, Daffydd Wiesner-Ellix and Andrew Suggett participating in Parkinsong. Picture: Amy Paton MEMBERS of Warrnambool’s Parkinson’s Disease support group were hoping to raise the roof of Macey’s Bistro on Wednesday.

Genetic analysis of CHCHD2 and CHCHD10 in Italian patients with Parkinson’s disease.

To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. In recent years, CHCHD2 and CHCHD10 mutations were reported to be associated with a broad spectrum of neurodegenerative diseases, including Parkinson’s disease , although with conflicting results in different populations.

Pathogenic LRRK2 variants are gain-of-function mutations that enhance …

LRRK2 mutations and risk variants increase susceptibility to inherited and idiopathic Parkinson’s disease, while recent studies have identified potential protective variants. This, and the fact that LRRK2 mutation carriers develop symptoms and brain pathology almost indistinguishable from idiopathic Parkinson’s disease, has led to enormous interest in this protein.

Voyager Therapeutics Announces Updates from Phase 1b Trial of…

Voyager Therapeutics, Inc. , a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system , today announced updates regarding the Phase 1b trial of VY-AADC01 for patients with advanced Parkinson’s disease. “The clinical trial of VY-AADC01 is progressing well with all five patients in Cohort 3 successfully completing treatment,” said Bernard Ravina, M.D., M.S., vice president of clinical development at Voyager Therapeutics.